ArticleBMC bioinformatics2025
OMetaNet: an efficient hybrid deep learning model based on multimodal data fusion and contrastive learning for predicting 2'-O-methylation sites in human RNA.
Article in BMC bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAccurately identifying RNA 2'-O-methylation (2OM) sites is a crucial step in gaining an in-depth understanding of RNA regulatory mechanisms. Although there are currently multiple prediction tools available, they still suffer from limited prediction accuracy and an inability to fully capture the associations between sequences and sites.
resultsThis study constructs a novel low-redundancy dataset and innovatively proposes the KN-PairMatrix encoding scheme, effectively addressing the research gap in sequence-site association analysis. Based on this foundation, we developed the deep learning framework OMetaNet, which integrates residual and downsampling-optimized CNN modules, Mamba network, and a proprietary cross-modal interactive fusion module. The framework incorporates a contrastive learning-driven adaptive hybrid loss function. Employing a progressive feature disentanglement strategy, it enhances the learning capability for 2OM site-specific patterns. Independent evaluation results demonstrate that OMetaNet significantly outperforms existing methods in predicting 2OM sites across all four nucleotide types.
conclusionsWe proposed a novel computational model, OMetaNet. Its unique design structure may potentially reshape the paradigm of transcriptome analysis, open up new directions for extracting modification site information, and show significant potential in biomarker research and cross-species generalization studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.